1. [18F]FDG PET/MRI combined with chest HRCT in early cancer detection: a retrospective study of 3020 asymptomatic subjects.
- Author
-
Peng, Liling, Liao, Yi, Zhou, Rui, Zhong, Yan, Jiang, Han, Wang, Jing, Fu, Yu, Xue, Le, Zhang, Xiaohui, Sun, Mingxiang, Feng, Gang, Meng, Zhaoting, Peng, Sisi, He, Xuexin, Teng, Gaojun, Gao, Xin, Zhang, Hong, and Tian, Mei
- Subjects
EARLY detection of cancer ,MAGNETIC resonance imaging ,ENDORECTAL ultrasonography ,RENAL cancer ,COMPUTED tomography ,POSITRON emission tomography ,DIAGNOSTIC imaging - Abstract
Purpose: PET/MRI has become an important medical imaging approach in clinical practice. In this study, we retrospectively investigated the detectability of fluorine-18 (
18 F)-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ([18 F]FDG PET/MRI) combined with chest computerized tomography (CT) for early cancer in a large cohort of asymptomatic subjects. Methods: This study included a total of 3020 asymptomatic subjects who underwent whole-body [18 F]FDG PET/MRI and chest HRCT examinations. All subjects received a 2โ4-year follow-up for cancer development. Cancer detection rate, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the [18 F]FDG PET/MRI with or without chest HRCT were calculated and analyzed. Results: Sixty-one subjects were pathologically diagnosed with cancers, among which 59 were correctly detected by [18 F]FDG PET/MRI combined with chest HRCT. Of the 59 patients (32 with lung cancer, 9 with breast cancer, 6 with thyroid cancer, 5 with colon cancer, 3 with renal cancer, 1 with prostate cancer, 1 with gastric cancer, 1 with endometrial cancer, and 1 with lymphoma), 54 (91.5%) were at stage 0 or stage I (according to the 8th edition of the tumor-node-metastasis [TNM] staging system), 33 (55.9%) were detected by PET/MRI alone (27 with non-lung cancers and 6 with lung cancer). Cancer detection rate, sensitivity, specificity, PPV, and NPV for PET/MRI combined with chest CT were 2.0%, 96.7%, 99.6%, 83.1%, and 99.9%, respectively. For PET/MRI alone, the metrics were 1.1%, 54.1%, 99.6%, 73.3%, and 99.1%, respectively, and for PET/MRI in non-lung cancers, the metrics were 0.9%, 93.1%, 99.6%, 69.2%, and 99.9%, respectively. Conclusions: [18 F]FDG PET/MRI holds great promise for the early detection of non-lung cancers, while it seems insufficient for detecting early-stage lung cancers. Chest HRCT can be complementary to whole-body PET/MRI for early cancer detection. Trial registration: ChiCTR2200060041. Registered 16 May 2022. Public site: https://www.chictr.org.cn/index.html [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF